Genomics and pharmacogenomics in anticancer drug development and clinical response

Genomics and pharmacogenomics in anticancer drug development and clinical response

Innocenti, F.

145,55 €(IVA inc.)

The availability of new molecular approaches to the selection of drug therapyis an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most cases the majority of treated patients do not have significant benefits fromthe treatment while they often experience moderate to severe toxicities. In ‘Pharmacogenomics, Anticancer Drug Discovery, and Response’ readers will find aseries of chapters addressing the role of genomic information in cancer therapy and in drug development representing a unique source, as it describes experimental approaches, statistical strategies, and clinical examples of the application of genomic medicine in oncology. This book provides the most comprehensive body of knowledge on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients. Comprehensive reference for researchers in the field of cancer pharmacogenomics and clinicians, from both academia and industry Provides a collection of multi-disciplinary topics Covers the most important aspects of pharmacogenomics applied to cancer patients INDICE: From the contents Genomic experimental approaches in oncology.- Toward the realisation of the promise of microarrays in oncology.- Cell based models to identify genetic variants contributing to anticancer drug response.- Proteomic analysis in cancer patients.- MicroRNAs and discovery of new targets.- Pharmacogenomics of the National Cancer Institute’s 60 tumor cell panel.- Use of single nucleotide polymorphism array for tumor aberrations in gene copy numbers.- Pharmacogenomics of toxicity and response of chemotherapy.- Concordance between tumor and germline DNA.- Epidermal growth factor receptor mutationsand sensitivity to selective kinase inhibitors in human lung cancer.- BCR-ABLmutations and imatinib resistance in chronic myeloid leukemia patients.- Roleof thymidylate synthase gene variations in colorectal cancer patients.- Thiopurines in the treatment of childhood acute lymphoblastic leukemia and genetic variants in the thiopurine S-methyltransferase gene.

  • ISBN: 978-1-58829-646-7
  • Editorial: Humana
  • Encuadernacion: Cartoné
  • Páginas: 730
  • Fecha Publicación: 01/09/2008
  • Nº Volúmenes: 1
  • Idioma: Inglés